| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Ilaria Marigo | |
| Elisa Peranzoni | |||
| Elena Masetto | |||
| Laura Pinton | |||
| Vincenzo Ingangi | |||
| P2860 | cites work | The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer | Q92239433 |
| Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report | Q92252911 | ||
| Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade | Q92376813 | ||
| Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab | Q92405933 | ||
| Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer | Q92421429 | ||
| Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma | Q92570413 | ||
| B cells and tertiary lymphoid structures promote immunotherapy response | Q92669559 | ||
| Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial | Q92685195 | ||
| Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer | Q92782506 | ||
| The Intersection between Tumor Angiogenesis and Immune Suppression | Q92827545 | ||
| The Endless Saga of Monocyte Diversity | Q92857692 | ||
| Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms | Q92883114 | ||
| Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study | Q92915460 | ||
| Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? | Q92951596 | ||
| Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer | Q93109975 | ||
| Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy | Q93119167 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards | Q26744395 | ||
| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy | Q27690653 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Inhibition of T cell proliferation by macrophage tryptophan catabolism | Q28142922 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells | Q28248489 | ||
| Type I interferon is selectively required by dendritic cells for immune rejection of tumors | Q28248500 | ||
| The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells | Q28275608 | ||
| Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia | Q28291815 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma | Q33591598 | ||
| CSF-1 receptor signaling in myeloid cells | Q33653719 | ||
| Retracted: Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer | Q33707131 | ||
| DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization | Q33773787 | ||
| PI3Kγ is a molecular switch that controls immune suppression | Q33822173 | ||
| The fate and lifespan of human monocyte subsets in steady state and systemic inflammation | Q33886544 | ||
| Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab | Q41469907 | ||
| Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade | Q41596176 | ||
| VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma | Q41636554 | ||
| Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid | Q41809337 | ||
| Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. | Q41974388 | ||
| Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D. | Q42032661 | ||
| The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. | Q42080528 | ||
| Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. | Q42682360 | ||
| Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. | Q42968783 | ||
| Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. | Q43048172 | ||
| Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity | Q43144666 | ||
| Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Q44017442 | ||
| Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer | Q44915586 | ||
| Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Q45070125 | ||
| Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. | Q45866300 | ||
| The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. | Q46142906 | ||
| Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody | Q47331134 | ||
| Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab | Q47369863 | ||
| Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer | Q47419988 | ||
| The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. | Q49979440 | ||
| Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab | Q50016409 | ||
| Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. | Q50030031 | ||
| Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma | Q50074098 | ||
| Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab | Q50198682 | ||
| Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy | Q50216662 | ||
| Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. | Q50676824 | ||
| Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. | Q51019599 | ||
| Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. | Q52586562 | ||
| T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. | Q52593234 | ||
| Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. | Q52681406 | ||
| Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. | Q52721746 | ||
| Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. | Q52758014 | ||
| Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. | Q52948211 | ||
| Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. | Q53697047 | ||
| Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. | Q54706557 | ||
| Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. | Q54940437 | ||
| Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. | Q55056515 | ||
| Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. | Q55119445 | ||
| Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. | Q55295587 | ||
| Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. | Q55323964 | ||
| The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. | Q55417775 | ||
| Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. | Q55421471 | ||
| Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. | Q55619003 | ||
| Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy | Q56879989 | ||
| Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma | Q56886545 | ||
| Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response | Q56890003 | ||
| An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 | ||
| Role of Macrophage Targeting in the Antitumor Activity of Trabectedin | Q56942258 | ||
| Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients | Q57788782 | ||
| High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy | Q57814130 | ||
| Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma | Q58547062 | ||
| Targeting macrophages: therapeutic approaches in cancer | Q58547311 | ||
| Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy | Q33912938 | ||
| Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes | Q34016867 | ||
| Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer | Q34031748 | ||
| CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. | Q34279134 | ||
| 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential | Q34303159 | ||
| VEGF as a mediator of tumor-associated immunodeficiency | Q34303192 | ||
| Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid | Q34339243 | ||
| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma | Q34647109 | ||
| Bevacizumab plus ipilimumab in patients with metastatic melanoma | Q35012765 | ||
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. | Q35263440 | ||
| Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation | Q35317995 | ||
| Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma | Q35329190 | ||
| Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma | Q35507112 | ||
| Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients | Q35616397 | ||
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. | Q35617517 | ||
| Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | Q35634752 | ||
| CD40/CD154 interactions at the interface of tolerance and immunity | Q35698455 | ||
| Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. | Q35835489 | ||
| Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer | Q35896426 | ||
| Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase | Q35925641 | ||
| Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients | Q36020800 | ||
| Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma | Q36206582 | ||
| Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. | Q36383913 | ||
| Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition | Q36413900 | ||
| Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. | Q36547923 | ||
| Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid | Q36644621 | ||
| Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | Q36730827 | ||
| Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. | Q36759111 | ||
| Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab | Q36821143 | ||
| Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study | Q36856816 | ||
| The prognostic landscape of genes and infiltrating immune cells across human cancers | Q36857285 | ||
| Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | Q36869774 | ||
| Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. | Q36973676 | ||
| Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model | Q37109800 | ||
| Targeting CD73 in the tumor microenvironment with MEDI9447. | Q37224639 | ||
| Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma | Q37237228 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism | Q37349845 | ||
| Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab | Q37548776 | ||
| Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy | Q37626265 | ||
| Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy | Q37718376 | ||
| Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy | Q37734285 | ||
| Roles of Sema4D and Plexin-B1 in tumor progression | Q37790755 | ||
| Regulation of lymphocyte function by adenosine | Q38024675 | ||
| Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells | Q38296397 | ||
| Development, history, and future of automated cell counters | Q38353347 | ||
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 | ||
| Biomarker: Predictive or Prognostic? | Q38590718 | ||
| PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. | Q38703214 | ||
| The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis | Q38721230 | ||
| T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells | Q38746598 | ||
| Biomarkers for Checkpoint Inhibition | Q38754521 | ||
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy | Q38786289 | ||
| Immune Checkpoint Therapy and the Search for Predictive Biomarkers | Q38816815 | ||
| Immunosuppressive activities of adenosine in cancer. | Q38840816 | ||
| Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment | Q38916286 | ||
| Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies | Q38917199 | ||
| Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | Q38996832 | ||
| Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity | Q39144794 | ||
| Integrating liquid biopsies into the management of cancer | Q39157824 | ||
| The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets | Q39161005 | ||
| Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment | Q39168810 | ||
| Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. | Q39201935 | ||
| The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis | Q39266495 | ||
| The immune contexture in cancer prognosis and treatment | Q39456999 | ||
| In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy | Q40218347 | ||
| Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. | Q40236161 | ||
| Myeloid-Derived Suppressor Cells | Q40385399 | ||
| Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab | Q40506025 | ||
| Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab | Q40713858 | ||
| Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab | Q40964128 | ||
| The Ratio of Peripheral Regulatory T Cells to Lox-1 PMN-MDSC Predicts the Early Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer Patients | Q58585965 | ||
| Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer | Q58595922 | ||
| Design of amidobenzimidazole STING receptor agonists with systemic activity | Q58599932 | ||
| Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037) | Q59128458 | ||
| Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab | Q59489483 | ||
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations | Q59793953 | ||
| Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q62514960 | ||
| Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab | Q62661800 | ||
| PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab | Q62661814 | ||
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma | Q62745893 | ||
| Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer | Q62929733 | ||
| Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma | Q64071263 | ||
| PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer | Q64085542 | ||
| Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment | Q64100389 | ||
| Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets | Q64112523 | ||
| Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel | Q64247150 | ||
| Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma | Q64259329 | ||
| Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients | Q64268841 | ||
| Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells | Q71607047 | ||
| Expression of Tie-2 by human monocytes and their responses to angiopoietin-2 | Q80358599 | ||
| Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 | ||
| The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients | Q88666290 | ||
| Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Q88973544 | ||
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | Q88985835 | ||
| Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab | Q89281994 | ||
| Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer | Q89397407 | ||
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) | Q89456538 | ||
| Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies | Q89640748 | ||
| Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases | Q90206556 | ||
| Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation | Q90252755 | ||
| Myeloid immunosuppression and immune checkpoints in the tumor microenvironment | Q90703794 | ||
| Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy | Q90730277 | ||
| Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade | Q90856138 | ||
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis | Q90904632 | ||
| The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors | Q90958052 | ||
| Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab | Q91019889 | ||
| Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab | Q91209500 | ||
| Improving efficacy of cancer immunotherapy through targeting of macrophages | Q91330299 | ||
| Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade | Q91392607 | ||
| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma | Q91451450 | ||
| The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Q91520697 | ||
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q91700806 | ||
| Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma | Q91862819 | ||
| A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma | Q91907652 | ||
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial | Q91958139 | ||
| Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? | Q92109994 | ||
| A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma | Q92133160 | ||
| Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma | Q92229967 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1590 | |
| P577 | publication date | 2020-07-24 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade | |
| P478 | volume | 11 |
Search more.